NVIV - InVivo Therapeutics Holdings Corp.
| Previous Close | 1.950 |
| Open | 1.950 |
| Bid | 1.930 x 2900 |
| Ask | 1.960 x 4000 |
| Day's Range | 1.950 - 1.960 |
| 52 Week Range | 1.630 - 56.250 |
| Volume | 8,113 |
| Avg. Volume | 323,915 |
| Market Cap | 15.185M |
| Beta | 2.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -21.639 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Business Wire•24 days ago
InVivo Therapeutics Announces Complete 12-Month Data from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury
InVivo Therapeutics Holdings Corp. (NVIV) today announced the complete 12-month results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). As previously announced by InVivo, 7 of 16 (44%) patients who reached the six-month primary endpoint visit in the INSPIRE study had an ASIA Impairment Scale (AIS) conversion at 6 months, which is the primary endpoint of the trial (defined as improvement in AIS grade from baseline for all evaluable patients at the six-month visit). The Objective Performance Criterion (OPC) (study success definition) for the study was a 25% AIS conversion rate based on the published conversion rates for thoracic spinal cord injury (SCI) reported in the literature.
- Associated Press•last month
InVivo: 2Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of $7.48 per share. In the final minutes of trading on Tuesday, the company's shares hit $2.08. A year ago, they were trading at $50. _____ ...
- Business Wire•last month
InVivo Therapeutics Reports 2018 Second Quarter Financial Results
- Significant Increase in Operating Efficiency; Operating Expenses Decreased by 59% -
- Business Wire•3 months ago
InVivo Therapeutics Announces Closing of $15.2 Million Public Offering, Including the Exercise of Underwriter’s Overallotment Option
InVivo Therapeutics Holdings Corp. (NVIV) today announced the closing of its public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to an aggregate of 6,242,811 shares of common stock together with warrants to purchase 6,242,811 shares of common stock, at a combined price to the public of $1.99 per pre-funded warrant and warrant. In addition, the underwriter exercised its option to purchase an aggregate of 989,997 additional shares of common stock and additional warrants to purchase 989,997 shares of common stock at the public offering price of $2.00 per share and warrant, less the underwriting discounts and commissions.
- Business Wire•3 months ago
InVivo Therapeutics Announces Pricing of $13.2 Million Underwritten Public Offering
InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of an underwritten public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to an aggregate of 6,242,811 shares of common stock together with warrants to purchase 6,242,811 shares of common stock, at a combined price to the public of $1.99 per pre-funded warrant and warrant. The gross proceeds from this offering are expected to be $13.2 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by InVivo Therapeutics.
- Simply Wall St.•4 months ago
Is InVivo Therapeutics Holdings Corp’s (NASDAQ:NVIV) Balance Sheet Strong Enough To Weather A Storm?
While small-cap stocks, such as InVivo Therapeutics Holdings Corp (NASDAQ:NVIV) with its market cap of US$11.35M, are popular for their explosive growth, investors should also be aware of their balanceRead More...
- Associated Press•5 months ago
InVivo: 1Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $3.34. InVivo shares have decreased 57 percent since the beginning of the year. In the final minutes of trading on ...
- Business Wire•5 months ago
InVivo Therapeutics Reports 2018 First Quarter Financial Results
InVivo Therapeutics Holdings Corp. today provided a business and clinical update and reported financial results for the quarter ended March 31, 2018.
- ACCESSWIRE•5 months ago
Today’s Research Reports on Stocks to Watch: vTv Therapeutics and InVivo Therapeutics
Shares of InVivo also headed higher after a reverse stock split this week. InVivo is also in the process of finalizing a lease assignment that the company expects will result in lease-related savings of approximately $3M through 2019.
- Business Wire•5 months ago
InVivo Therapeutics Provides Business Update
InVivo Therapeutics Holdings Corp. today provided a general business update. The company is announcing a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock.
- Business Wire•6 months ago
InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) Findings
InVivo Therapeutics Holdings Corp. today announced top-line findings from its CONTEMPO Registry Study, designed to provide comprehensive natural history benchmarks for Neuro-Spinal Scaffold™ clinical study results.
- Associated Press•6 months ago
InVivo reports 4Q loss
The Cambridge, Massachusetts-based company said it had a loss of 13 cents per share. For the year, the company reported that its loss widened to $26.7 million, or 81 cents per share. The company's shares ...
- Business Wire•6 months ago
InVivo Therapeutics Reports 2017 Year-end Financial Results
InVivo Therapeutics Holdings Corp. today reported financial results for the year ended December 31, 2017.
- Simply Wall St.•6 months ago
Is It Time To Buy InVivo Therapeutics Holdings Corp (NASDAQ:NVIV)?
InVivo Therapeutics Holdings Corp (NASDAQ:NVIV), a medical equipment company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. Less-covered,Read More...
- ACCESSWIRE•6 months ago
Today’s Research Reports on Stocks to Watch: Johnson & Johnson and InVivo Therapeutics
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Shares of Johnson & Johnson saw a slight close in the green yesterday despite announcing that the average price paid for its medicines had dropped last year. ...
- Business Wire•6 months ago
InVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold™ in Patients with Acute Spinal Cord Injury
InVivo Therapeutics Holdings Corp. today announced that the company has received supplemental Investigational Device Exemption approval from the US Food and Drug Administration for a second pivotal clinical study of the company’s Neuro-Spinal Scaffold™ in patients with acute spinal cord injury .
- Business Wire•7 months ago
InVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive Officer
InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., has been appointed President and Chief Executive Officer of InVivo, having been appointed the company’s Acting CEO in December 2017.
- ACCESSWIRE•8 months ago
Blog Exposure - InVivo Therapeutics Signs Share Repurchase Agreement with Lincoln Park Capital
LONDON, UK / ACCESSWIRE / January 29, 2018 / Active-Investors.com has just released a free research report on InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV ) ("InVivo Therapeutics"). If you ...
- Business Wire•8 months ago
InVivo Therapeutics Announces Purchase Agreement for up to $15 Million with Lincoln Park Capital
InVivo Therapeutics Holdings Corp. today announced that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC , a
- Business Wire•9 months ago
InVivo Therapeutics Announces Latest Results from INSPIRE and Provides Update on Proposed Clinical Path Forward
InVivo Therapeutics Holdings Corp. today announced the latest results from The INSPIRE Study .
- Business Wire•9 months ago
InVivo Therapeutics Announces Executive Management and Board Changes
InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., has been appointed Acting Chief Executive Officer of InVivo, replacing Mark D. Perrin, who has resigned as Chief Executive Officer and Chairman of InVivo’s Board of Directors.
- Associated Press•11 months ago
InVivo reports 3Q loss
The Cambridge, Massachusetts-based company said it had a loss of 28 cents per share. In the final minutes of trading on Monday, the company's shares hit $1.45. A year ago, they were trading at $4.40. _____ ...
- Simply Wall St.•11 months ago
What Is InVivo Therapeutics Holdings Corp’s (NVIV) Share Price Doing?
InVivo Therapeutics Holdings Corp (NASDAQ:NVIV), a healthcare equipment and supplies company based in United States, saw a significant share price rise of over 20% in the past couple of monthsRead More...
- Business Wire•11 months ago
InVivo Therapeutics Announces Oral Platform Presentation at 2017 Congress of Neurological Surgeons Annual Meeting
InVivo Therapeutics Holdings Corp. today announced that Stuart Lee, M.D., Investigator at Vidant Medical Center in Greenville, North Carolina, will be giving an oral platform presentation titled “Histopathology of Necrotic Spinal Cord Tissue Exudate Collected During Surgical Implantation of a Biodegradable Scaffold Following Acute Spinal Cord Injury: Pre-clinical and Clinical Findings” at the 2017 ...
